Revexa Pharma Tirzepatide 40mg Pen

Revexa Pharma Tirzepatide is a GLP-1/GIP dual receptor agonist that delivers more aggressive fat loss than single-agonist compounds like Semaglutide. Clinical trials demonstrated an average weight loss of 22.5% of body weight over 72 weeks, significantly exceeding Semaglutide’s 14.9%. Tirzepatide works by activating both GLP-1 and GIP receptors simultaneously, producing stronger appetite suppression, improved insulin sensitivity, and enhanced metabolic signalling compared to GLP-1-only drugs.

How Tirzepatide Differs from Semaglutide

Semaglutide activates GLP-1 receptors only. Tirzepatide adds GIP receptor activation, which amplifies the appetite-suppressing signal and improves glucose metabolism through a complementary pathway. The practical result is greater weekly weight loss, faster onset of appetite suppression, and better metabolic outcomes. For users who have plateaued on Semaglutide or who want more aggressive results from the outset, Tirzepatide is the logical next step up.

For the most advanced option available, Retatrutide adds a third receptor (glucagon) on top of GLP-1 and GIP, producing the highest fat loss of any peptide in clinical trials (24.2% body weight).

Dosage Protocol

• Week 1-4: 2.5mg once weekly (subcutaneous injection)
• Week 5-8: 5mg once weekly
• Week 9-12: 7.5-10mg once weekly
• Week 13+: 10-15mg once weekly (target maintenance dose)
• Injection site: abdomen or thigh. Rotate sides weekly
• Same day each week. Consistency matters more than time of day

Who Benefits from Tirzepatide

• Bodybuilders in cutting phases who want non-stimulant appetite suppression alongside anabolic compounds
• Users who plateaued on Semaglutide and need stronger appetite suppression
• Post-bulk weight management to control appetite rebound after Dianabol or Deca cycles
• Users who cannot tolerate Clenbuterol due to cardiovascular sensitivity or insomnia

Side Effects

• Nausea: most common during dose escalation. Resolves for most users within 2-4 weeks at each dose level. Taking the injection at bedtime minimises daytime nausea
• Diarrhoea or constipation: GI adjustment. Usually temporary
• Pronounced appetite suppression: maintain minimum 2g protein per kg bodyweight to prevent muscle loss
• No testosterone suppression, no liver toxicity, no PCT required

Key Facts

• Active ingredient: Tirzepatide
• Manufacturer: Revexa Pharma
• Class: GLP-1/GIP dual receptor agonist
• Half-life: approximately 5 days (once-weekly dosing)
• Storage: refrigerate. Protect from light

Browse our full weight loss range including Semaglutide, Retatrutide, and Clenbuterol.